2014
Treatment of Hodgkin Lymphoma: A 50-Year Perspective
Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, DeVita VT. Treatment of Hodgkin Lymphoma: A 50-Year Perspective. Journal Of Clinical Oncology 2014, 32: 163-168. PMID: 24441526, DOI: 10.1200/jco.2013.53.1194.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBleomycinClinical Trials as TopicCyclophosphamideDacarbazineDisease-Free SurvivalDoxorubicinEtoposideEuropeHistory, 20th CenturyHodgkin DiseaseHumansMechlorethamineNeoplasm StagingPositron-Emission TomographyPrednisoneProcarbazineSurvival RateTomography, X-Ray ComputedTreatment OutcomeVinblastineVincristine
1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDisease
1993
Dose Intensity
SURBONE A, DeVITA V. Dose Intensity. Annals Of The New York Academy Of Sciences 1993, 698: 279-288. PMID: 8279768, DOI: 10.1111/j.1749-6632.1993.tb17219.x.Peer-Reviewed Original ResearchCHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma
Longo D, DeVita V, Young R. CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma. New England Journal Of Medicine 1993, 329: 580-582. PMID: 7687747, DOI: 10.1056/nejm199308193290817.Peer-Reviewed Original Research
1991
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas
Fisher R, Longo D, DeVita V, Hubbard S, Miller T, Young R. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Annals Of Oncology 1991, 2: 33-35. PMID: 1710487, DOI: 10.1093/annonc/2.suppl_1.33.Peer-Reviewed Original ResearchConceptsDisease-free survivalProMACE-MOPPCR rateComplete remissionProMACE-CytaBOMHodgkin's lymphomaLong-term disease-free survivalLong-term disease-free survivorsSurvival curvesStage IIDisease-free survival curvesFirst-generation regimensThird-generation regimensPhase II studyDisease-free survivorsOverall survival curvesSouthwest Oncology GroupCooperative group settingHigh-grade NHLNational Cancer InstituteSame time pointsVs 53Aggressive NHLII studyOncology GroupSuperiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal Of Clinical Oncology 1991, 9: 25-38. PMID: 1702144, DOI: 10.1200/jco.1991.9.1.25.Peer-Reviewed Original ResearchConceptsDaily days 1ProMACE-MOPPComplete remissionProMACE-CytaBOMDay 1Day 8Complete respondersSmall noncleaved-cell lymphomaComplete response rateCo-trimoxazole prophylaxisDouble-strength tabletProMACE-CytaBOM regimenTreatment-related causesTreatment-related mortalityPneumocystis carinii pneumoniaDiffuse aggressive lymphomasPeriod of treatmentDay 1 treatmentCombination chemotherapyAggressive lymphomaCarinii pneumoniaMalignant lymphomaEffective treatmentPatientsResponse rate
1989
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
Longo D, Glatstein E, Duffey P, Ihde D, Hubbard S, Fisher R, Jaffe E, Gilliom M, Young R, DeVita V. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. Journal Of Clinical Oncology 1989, 7: 1295-302. PMID: 2788716, DOI: 10.1200/jco.1989.7.9.1295.Peer-Reviewed Original ResearchConceptsInvolved field radiation therapyRadiation therapyComplete remissionAggressive lymphomaCoronary artery bypass surgeryInvolved-field radiation therapyEarly hematogenous disseminationLocalized aggressive lymphomaTreatment-related deathsClinical stage IHigh-dose methotrexateArtery bypass surgeryCombination chemotherapy programsCycles of treatmentMedian followAggressive histologyBypass surgeryLeucovorin rescueChemotherapy programCombination chemotherapyHospital admissionLocal therapyHematogenous disseminationEffective treatmentLymphoma histology
1988
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Young R, Longo D, Glatstein E, Ihde D, Jaffe E, DeVita V. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Seminars In Hematology 1988, 25: 11-6. PMID: 2456618.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideEvaluation Studies as TopicHumansLeucovorinLeukemiaLeukemia, Radiation-InducedLymph NodesLymphoma, Non-HodgkinMechlorethamineMethotrexateNeoplasms, Multiple PrimaryNeoplasms, Radiation-InducedPalliative CarePrednisoneProcarbazineRandom AllocationVincristineConceptsAdvanced indolent lymphomaLimited radiation therapyTotal nodal irradiationIndolent lymphomaRadiation therapyModality treatmentInitial treatmentAggressive combined modality therapyCombined modality therapyEvaluable patientsInduction therapyInitial therapyNodal irradiationFirst remissionInitial remissionFrequent relapsesMedian durationModality therapySystemic therapyCombination chemotherapyMedian timeHistologic progressionLonger survivalPatient's diseasePatients
1986
Hematologic malignancies: non-Hodgkin's lymphomas.
DeVita V. Hematologic malignancies: non-Hodgkin's lymphomas. Hospital Practice 1986, 21: 103-18. PMID: 2427535.Peer-Reviewed Original Research
1985
ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Fisher R, Young R, Longo D, DeVita V. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Seminars In Oncology 1985, 12: 29-32. PMID: 2579441.Peer-Reviewed Original ResearchConceptsComplete remissionCombination chemotherapyAdvanced stageComplete response rateLong-term survivalMOPP combination chemotherapyC-MOPPComplete respondersNew regimenHodgkin's lymphomaBurkitt's lymphomaDiffuse lymphomaResponse rateFatal diseaseLymphomaPatientsDeath rateNCI studyHigh gradeRemissionChemotherapyDiseaseLarge cellsMyelosuppressionRegimen
1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier R, Anderson J, Costello W, Rosner G, Horton J, Glick J, Hines J, Berard C, DeVita V. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Annals Of Internal Medicine 1984, 101: 447-56. PMID: 6089632, DOI: 10.7326/0003-4819-101-4-447.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCarmustineClinical Trials as TopicCombined Modality TherapyCyclophosphamideFemaleGastrointestinal DiseasesHematologic DiseasesHodgkin DiseaseHumansMaleMechlorethamineNeoplasm StagingPeripheral Nervous System DiseasesPrednisoneProcarbazineRandom AllocationVinblastineVincristineConceptsAdvanced Hodgkin's diseaseHodgkin's diseaseUntreated patientsEastern Cooperative Oncology Group studyDuration of complete remissionRandomized prospective studyTreatment of patientsMOPP regimenHematologic toxicityInduction chemotherapyComplete remissionChemotherapy regimensRemission rateNeurological toxicityProspective studyMOPPRemissionTherapeutic benefitChemotherapyPatientsInduction phaseDiseaseToxicityGroup studyDurationProlonged initial remission in patients with nodular mixed lymphoma.
Longo D, Young R, Hubbard S, Wesley M, Fisher R, Jaffe E, Berard C, DeVita V. Prolonged initial remission in patients with nodular mixed lymphoma. Annals Of Internal Medicine 1984, 100: 651-6. PMID: 6370065, DOI: 10.7326/0003-4819-100-5-651.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideFemaleHumansLeucovorinLymphoma, FollicularMaleMechlorethamineMethotrexateMiddle AgedNeoplasm StagingPrednisoneProcarbazinePrognosisRetrospective StudiesTime FactorsVincristineConceptsNodular mixed lymphomaComplete response rateMixed lymphomaComplete respondersInitial remissionMedian survivalResponse rateOverall complete response ratePrimary treatment regimensBone marrow involvementLactate dehydrogenase levelsNational Cancer InstituteAverage remissionB symptomsComplete remissionFirst remissionMarrow involvementShorter survivalTreatment regimensDehydrogenase levelsRemissionPatientsStage ICancer InstituteLymphoma
1983
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphoma
1981
Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma
Broder S, Callihan T, Jaffe E, DeVita V, Strober W, Bartter F, Waldmann T. Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. Gastroenterology 1981, 80: 166-168. PMID: 7450403, DOI: 10.1016/0016-5085(81)90208-0.Peer-Reviewed Original ResearchConceptsIntestinal lymphangiectasiaCombination chemotherapyMalignant lymphomaUndifferentiated malignant lymphomaSystemic combination chemotherapyGastrointestinal protein lossProtein lossB-cell originSerum protein concentrationMonoclonal B-cell originGastrointestinal symptomsRecurrent vomitingMassive edemaIntestinal lymphangiectasisIntestinal lymphaticsGastrointestinal tractNeoplastic cellsPatientsLymphomaLymphangiectasiaInitial evaluationYr durationChemotherapyEdemaDisease
1980
Advances in the multimodal primary management of cancer.
DeVita V, Henney J, Weiss R. Advances in the multimodal primary management of cancer. Advances In Internal Medicine 1980, 26: 115-29. PMID: 7013437.Peer-Reviewed Original Research
1979
The dilemma regarding postoperative chemotherapy in primary carcinoma of the colon.
Weiss R, DeVita V. The dilemma regarding postoperative chemotherapy in primary carcinoma of the colon. Journal Of The American College Of Surgeons 1979, 149: 267-71. PMID: 380029.Peer-Reviewed Original Research
1978
Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, DeVita V. Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy. New England Journal Of Medicine 1978, 299: 1261-1266. PMID: 101843, DOI: 10.1056/nejm197812072992301.Peer-Reviewed Original ResearchConceptsAdvanced ovarian adenocarcinomaFour-drug combinationOverall response rateOvarian adenocarcinomaComplete remissionMedian survivalResidual diseaseResponse rateHigher overall response rateExtensive residual diseaseFour-drug regimenProspective clinical trialsLonger median survivalMinimal residual diseaseAdvanced diseaseCombination chemotherapyClinical trialsSevere toxicityMelphalanPatientsAdenocarcinomaDiseaseRemissionTrialsSurvivalChemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma.
Johnson R, Canellos G, Young R, Chabner B, DeVita V. Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma. Journal Of The National Cancer Institute 1978, 62: 321-5. PMID: 580598.Peer-Reviewed Original ResearchMeSH KeywordsCyclophosphamideDrug Therapy, CombinationFemaleHumansLymphoma, Non-HodgkinMaleMiddle AgedPrednisoneTime FactorsVincristineConceptsTotal body irradiationTotal body irradiation patientsEvaluate new therapeutic approachesSurvival rateStage III-IVCandida sepsisDurable remissionsLymphocytic lymphomaBody irradiationMalignant lymphomaSevere granulocytopeniaMyeloproliferative disordersLate complicationsIII-IVChemotherapy complicationsInduction treatmentSurvival advantageNeurotoxic reactionsTherapeutic approachesLymphomaChemotherapyPatientsComplicationsRadiotherapySurvival
1977
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Young R, Johnson R, Canellos G, Chabner B, Brereton H, Berard C, DeVita V. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Journal Of The National Cancer Institute 1977, 61: 1153-9. PMID: 332349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood PlateletsClinical Trials as TopicCyclophosphamideDrug Therapy, CombinationFemaleHumansLeukocytesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm StagingPrednisoneProcarbazineProspective StudiesRadiation DosageRadiation InjuriesRemission, SpontaneousTime FactorsVincristineConceptsHigher overall response rateCyclic combination chemotherapyOverall response rateCombination chemotherapyMedian followupResponse rateSimilar complete remission ratesRelapse-free survival rateComparison of chemotherapyMonths median followupComplete remission rateOverall median survivalDisease-free survivalTotal body irradiationNodular mixed lymphomaInduction regimenInduction therapyComplete remissionMedian survivalProspective trialRemission rateUntreated patientsMixed lymphomaMalignant lymphomaNodular lymphomaCombination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.
Anderson T, Bender R, Fisher R, DeVita V, Chabner B, Berard C, Norton L, Young R. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Journal Of The National Cancer Institute 1977, 61: 1057-66. PMID: 71205.Peer-Reviewed Original ResearchAdolescentAdultAgedBleomycinChildClinical Trials as TopicCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHumansLymphomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission, SpontaneousTime FactorsVincristine